Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2026 ,inter alia, to consider and approve Board Meeting intimation for ....

Exceptional itemResults View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹1422.00

prior close

₹1420.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+2.0%-0.3% vs market

Pharmaceuticals peers, median of 155sector+0.7%+1.0% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.3

15m

-1.5

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+2.0-0.3+0.7+1.0

Next day

+3.8+1.6+2.2-0.1+3.9

+4.5+3.5+1.0+0.9+3.6

+2.7+2.2+0.5+0.5+2.2

+5.8+6.0-0.1+3.0+2.9

+3.4+7.4-3.9+3.3+0.1

+8.3+5.5+2.8+2.0+6.3

15d

+11.5+7.1+4.3+3.6+7.8

+13.6+1.3+12.3-0.9+14.5

+9.0-8.1+17.1-10.9+19.9

+18.1+12.1+6.0+4.3+13.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Corona Remedies Ltd has informed the stock exchanges that its Board of Directors will meet on Monday, February 2, 2026. The key agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2025. The company has also confirmed that the trading window for dealing in its securities remains closed until Wednesday, February 4, 2026, in line with insider trading regulations.

Likely market impact

This is a routine pre-results announcement and does not carry any direct fundamental impact on the stock. Investors should watch for the actual Q3FY26 results on or after February 2, 2026, as any meaningful revenue or profit deviation could move the stock. The closed trading window signals that insiders are restricted from trading until results are published.

By the numbersConsolidated · Q3 FY26

	Q3 FY26	Year ago	Change
Revenue	₹342.4 Cr	—	—
Operating profit	₹72.05 Cr	—	—
Profit after tax	₹41.27 Cr	—	—
EBITDA margin	18.7%	—	—

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income. No year-ago figures on this basis yet, so no comparison.